Study of rare liver cancers in France
Part of Cancer, Digestive system clinical trials.
This study looks at people with rare types of liver cancer to learn more about the disease. If you have one of these rare liver cancers, your information could help doctors understand these cancers better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with a rare liver cancer such as hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma, or hepatic angiosarcoma.
- Your diagnosis was made after January 1, 2018.
- If you are alive, you have not objected to participating in the research.
- You have social security coverage.
- A sample of your tumor (tumor block) is available for study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with bile duct cancer or certain liver cancers to better understand their disease. You might be included if you meet the diagnosis and basic participation requirements.
This study looks at people with rare solid tumors or lymphoma to understand their cancer’s genetic changes. It collects blood and existing tissue samples (from standard care) for DNA testing and gathers health information to help improve knowledge about rare cancers.
This study collects blood and tumor tissue samples from people with primary liver cancer who are starting their first treatment (systemic therapy or surgery). The samples help researchers learn more about these cancers and how to improve future treatments.
This study follows people with hepatocellular carcinoma (HCC), a type of liver cancer, to learn how it changes over time. It may help improve understanding of which patients benefit from different care approaches.
This trial looks at a patient’s “metabolic profile” (how the body’s chemicals are used) in people with certain liver and pancreatic tumors. It may help doctors better understand these cancers and improve how they are evaluated for treatment.
This study helps doctors better understand your cancer by doing tumor/cancer profiling as part of research. If you qualify, your participation may help improve how cancers are studied and matched with future treatments.
Hear when a new Fibrolamellar Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.